PIPA: A phase Ib study of β-isoform sparing phosphatidylinositol 3-kinase (PI3K) inhibitor taselisib (T) plus palbociclib (P) and fulvestrant (FUL) in PIK3CA-mutant (mt) ER-positive and taselisib (T) plus palbociclib (P) in PIK3CA-mutant (mt) ER-negative advanced breast cancer.

被引：6

作者：

Pascual, Javier

MacPherson, Iain R.

Armstrong, Anne Caroline

Ward, Sarah Emily

Parmar, Mona

Turner, Alison Joanne

Bye, Hannah

Proszek, Paula

Dodson, Andrew

Garcia-Murillas, Isaac

King, Jenny

Hall, Emma

Finneran, Laura

Lopez, Juanita Suzanne

Okines, Alicia Frances Clare

Ring, Alistair E.

Turner, Nicholas C.

机构：

[1] Royal Marsden Hosp, London, England

[2] Inst Canc Res, London, England

[3] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[4] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England

[5] Inst Canc Res, Sutton, Surrey, England

[6] Royal Marsden Inst Canc Res, London, England

[7] Royal Marsden NHS Fdn Trust, London, England

[8] Inst Canc Res, Clin Trials & Stat Unit, London, England

[9] Inst Canc Res, Drug Dev Unit, Sutton, Surrey, England

[10] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.1051

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1051

引用

页数：2

共 46 条

[21] A first-in-human phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients with PIK3CA-mutant solid tumors
Juric, Dejan
Kalinsky, Kevin
Oliveira, Mafalda
Cervantes, Andres
Bedard, Philippe
Krop, Ian
Hamilton, Erika
Schmid, Peter
Varga, Andrea
Turner, Nick
Italiano, Antoine
Saura, Cristina
Gambardella, Valentina
Veitch, Zachary
Dickmann, Leslie
Kotani, Naoki
Fredrickson, Jill
Kapp, Amy
Hutchinson, Katie
Royer-Joo, Stephanie
Vaze, Anjali
Schutzman, Jennifer
Jhaveri, Komal
CANCER RESEARCH, 2020, 80 (04)
[22] Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells
Fujimoto, Yumi
Morita, Tomoko Yamamori
Ohashi, Akihiro
Haeno, Hiroshi
Hakozaki, Yumi
Fujii, Masanori
Kashima, Yukie
Kobayashi, Susumu S.
Mukohara, Toru
SCIENTIFIC REPORTS, 2020, 10 (01)
[23] Mutation analysis of circulating tumour DNA from baseline and study discontinuation samples in SANDPIPER, a phase III study of taselisib or placebo with fulvestrant in oestrogen receptor-positive, human epidermal growth factor receptor 2-negative, PIK3CA-mutant advanced breast cancer
Jacot, W.
Savage, H. M.
Dent, S.
Cortes, J.
Im, Y-H.
Dieras, V. C.
Harbeck, N.
Krop, I. E.
Chen, J.
Sokol, E.
Schimmoller, F.
Hsu, J.
De Laurentiis, M.
Wilson, T. R.
ANNALS OF ONCOLOGY, 2020, 31 : S16 - S16
[24] Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells
Yumi Fujimoto
Tomoko Yamamori Morita
Akihiro Ohashi
Hiroshi Haeno
Yumi Hakozaki
Masanori Fujii
Yukie Kashima
Susumu S. Kobayashi
Toru Mukohara
Scientific Reports, 10
[25] Phase I study of the PI3Kα inhibitor BYL719 plus fulvestrant in patients with PIK3CA-altered and wild type ER+/HER2-locally advanced or metastatic breast cancer
Janku, Filip
Juric, Dejan
Cortes, Javier
Rugo, Hope
Burris, Howard A.
Schuler, Martin
Deschler-Baier, Barbara
Middleton, Mark R.
Gil-Martin, Marta
Berlin, Jordan
Winer, Eric
Bootle, Douglas
Blumenstein, Lars
Demanse, David
Coughlin, Christina
Quadt, Cornelia
Baselga, Jose
CANCER RESEARCH, 2015, 75
[26] Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC)
Piccart, M.
Ruiz Borrego, M.
Duhoux, F.
Arkenau, H-T.
Doger de Speville, B.
Wildiers, H.
Campone, M.
Tosi, D.
Garcia-Corbacho, J.
Jimenez, B.
Escriva-de Romani, S.
Wardley, A. M.
Tassone, P.
Boni, V.
Jerez, Y.
Aftimos, P. G.
Hennequin, A.
Amair-Pinedo, F.
Pellacani, A. U. E.
Laurent, D. O.
ANNALS OF ONCOLOGY, 2020, 31 : S386 - S386
[27] A phase Ib study of PI3Kα inhibitor risovalisib mesylate in combination with fulvestrant in patients with PIK3CA-mutated, HR+/HER2-advanced breast cancer
Wu, Jiong
Zhang, Jian
Li, Man
Cai, Li
Sun, Tao
Ouyang, Quchang
Meng, Yanchun
Shi, Yehui
Wang, Chuan
Liu, Qiang
Lu, Yongkui
Yin, Yongmei
Chen, Qianjun
Chen, Lilin
Wang, Haitao
Cui, Jiuwei
Liao, Ning
Wang, Shubin
Tu, Yi
Yan, Min
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[28] A Phase I Study Evaluating GDC-0941, a Pan-phosphoinositide-3 Kinase (PI3K) Inhibitor, In Patients (pts) With Advanced Solid Tumours, Multiple Myeloma, and PIK3Ca Mutant (mt) Tumours
Banerjee, S.
Baird, R.
Basu, B.
Shah, K.
Tunariu, N.
Garcia, V. Moreno
Corral, J.
Mazina, K.
Levy, G.
de Bono, J.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : S159 - S159
[29] MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01)
Piccart, M.
Borrego, M. Ruiz
Arkenau, H-T.
Escriva-De-Romani, S. I.
Howell, S. J.
Hennequin, A.
Jimenez-Rodriguez, B.
Del Conte, G.
Simonelli, M.
Palleschi, M.
Duhoux, F.
De Speville Uribe, B. Doger
Curigliano, G.
Waters, S.
Aftimos, P. G.
Wildiers, H.
Tosi, D.
Amair-Pinedo, F.
Pellacani, A. U. E.
Laurent, D. O.
ANNALS OF ONCOLOGY, 2021, 32 : S478 - S479
[30] Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer
Jhaveri, Komal L.
Accordino, Melissa K.
Bedard, Philippe L.
Cervantes, Andres
Gambardella, Valentina
Hamilton, Erika
Italiano, Antoine
Kalinsky, Kevin
Krop, Ian E.
Oliveira, Mafalda
Schmid, Peter
Saura, Cristina
Turner, Nicholas C.
Varga, Andrea
Cheeti, Sravanthi
Hilz, Stephanie
Hutchinson, Katherine E.
Jin, Yanling
Royer-Joo, Stephanie
Peters, Ubong
Shankar, Noopur
Schutzman, Jennifer L.
Juric, Dejan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (33)

← 1 2 3 4 5 →